is now

Please update your bookmarks and favorites.
You will be taken to the new site in a few seconds.

Expert MIPS Consulting Services

Helping You Successfully Participate in MIPS

The MIPS decisions you make today will hit your practice's bottom line tomorrow. Inform Diagnostics offers consulting services to help providers optimize their CMS reimbursements. Under the MIPS (Merit-based Incentive Payment System) program, your data from 2017 is already affecting your revenue for 2019.

What is MIPS?

MIPS was created by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) to streamline multiple value-based programs including Meaningful Use (MU), Physician Quality Reporting System (PQRS), Value-Based Modifier (VBM), along with brand new Clinical Performance Improvement Activities (CPIA).

MIPS is one of two possible payment paths that is available to physicians, physician assistants and nurse practitioners under MACRA.

Participation is not optional! As a budget-neutral program, penalties from the low-performing providers will be used to fund payments to high-performing providers.

Merit-based Incentive Payment System

What makes Inform Diagnostics consulting services unique?

Our MIPS Maximizer exclusive software tool helps providers and practices participate successfully in MIPS.

  • What We Do: Our certified Health IT consultants analyze the complex data (with complex terminology) from your QRUR report twice per year to identify actionable opportunities for your practice.
  • What We Deliver: We provide specific action items in a condensed report based on our analysis of your QRUR report, and we provide assistance to implement new processes.
  • How We Help: Inform Diagnostics helps practices by monitoring patient cost and quality data through workflow implementation in your office. We help you navigate these programs so that you can stay independent.
    • Maximize your reimbursement opportunity with CMS and commercial payors by showing high quality at optimal costs
    • Enhance your Physician and Practice ratings on CMS’s new Physician Compare website
    • Prepare for value-based payment systems from commercial payors. United Healthcare saved $38 billion in 2014 by engaging 20% of its network providers in value-based contracts. Experts project that 50%–70% of all payments will funnel through value-based contracts by 2020.

Detailed workflow and program know how is critical to optimizing performance AND maximizing reimbursement!

Ask us about these MIPS consulting services:

  • MIPS Maximizer- Quality Resource & Use Report analysis
  • Clinical Practice Improvement Activities (CPIA)
  • Advancing Care information (ACI)
  • Quality guidance and submission assistance*
  • Audit support
  • Security Risk Assessment (SRA)*
  • HIPAA Certification Course*
  • Workflow guidance and support
  • Attestation assistance

* Separately available services

Our fee-based consulting services are offered completely independent from our premier pathology services. Clients are not required to refer.

Start successfully participating in MIPS. Speak with one of our Technical Directors today.

MIPS Performance Categories and Scoring Simplified

MIPS Pie Charts

As of January 1, 2017, Medicare Part B eligible clinicians (ECs) will be measured annually in four performance categories to derive a MIPS score between 0 and 100. That score will determine positive, neutral, or negative adjustments to each clinician’s annual Medicare reimbursement.

MIPS Scoring

CMS will shift these point values in 2018 and beyond, but clinicians’ 2017 performance in just two of these categories—ACI and Quality—will comprise 85% of your maximum potential score.

Your scores will be publically available to consumers via the Centers for Medicare & Medicaid Services (CMS) Physician Compare website.

What are the financial impacts of MIPS Year by Year?

Revenue Adjustment Timeline

Contact us to find out your specific Medicare incentive and penalty dollars at risk in the MIPS program.

What are the reputational impacts of MIPS?

CMS has a public website that measures and compares physicians to their peers. The CMS Physician Compare website contains MIPS performance scores and ranks physicians nationally through a five star rating system. Under MIPS, your reputation score is determined largely by a single factor: QUALITY.

Learn how you can impact your public score! Speak with one of our Technical Directors today.

What steps can I take now to successfully perform in MIPS while maximizing incentives?

MIPS provides clinicians the flexibility to choose the activities and measures that are most meaningful to their practice to demonstrate performance.

MACRA Option Gauge

Discover how you can earn 71 points and gain the most incentive dollars. Start here.

Contact Inform Diagnostics to learn how we can assist your practice with MIPS.

Call 866.588.3280 today for more information or contact us using our online form.

Our use of EMA became exponentially more efficient once we partnered with Miraca.
— Rihanna Flanagan, PA-C,
Associates South Shore Dermatology, Quincy, Mass.

Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.

Recent News

January 8, 2018

Miraca Life Sciences Announces Company Name Change to Inform Diagnostics

IRVING, Texas, January 8, 2018 — Miraca Life Sciences announced today that it has changed its name to Inform Diagnostics effective immediately. The company was acquired in November by Avista Capital Partners from previous owner Miraca Holdings. The name Inform Diagnostics and new logo were chosen to highlight the company’s focus on providing pathology and diagnostic capabilities that together help […]

Continue reading

November 20, 2017

Avista Capital Partners Completes Acquisition of Miraca Life Sciences

IRVING, Texas and NEW YORK, Nov. 20, 2017 — Avista Capital Partners (“Avista”), a leading private equity firm, today announced the completion of its acquisition of Miraca Life Sciences (“MLS” or the “Company”) from Miraca Holdings Inc.

Continue reading the press release at the Avista website.

Continue reading

October 16, 2017

Renflexis™ is Latest Addition to Therapeutic Drug Monitoring by Miraca Life Sciences

IRVING, Texas, October 16, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand in clinical pathology: its InformTx™ therapeutic drug monitoring (TDM) has begun the validation process for Renflexis™ (infliximab-abda), a biosimilar of Remicade® (infliximab). Testing will be commercially available in early November. Since launching the InformTx service in June 2016, Miraca Life Sciences […]

Continue reading

October 3, 2017

Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States

MLS to market Biocept’s proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future

SAN DIEGO (October 3, 2017) – Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered […]

Continue reading

September 22, 2017

Avista Capital Partners to Acquire Miraca Life Sciences

IRVING, TX, NEW YORK, NY, and TOKYO, September 22, 2017 – Avista Capital Partners (“Avista”), a leading private equity firm, and Miraca Holdings Inc. (“MHD”) announced today that Avista has signed a definitive agreement to acquire Miraca Life Sciences (“MLS” or “the Company”), a wholly-owned subsidiary of Miraca Holdings Inc. Continue reading press release

Continue reading